IL13 and atopic eczema: According to the DrugBank database, multiple drugs targeting IL-13 and IL-33, or carried by FABP3 to the heart, have been developed and either approved or are under investigation for conditions such as atopic dermatitis, asthma, chronic obstructive pulmonary disease and bacterial growth.